CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
Titel:
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
Auteur:
Swan, D. Henderson, R. McEllistrim, C. Naicker, S.D. Quinn, J. Cahill, M.R. Mykytiv, V. Lenihan, E. Mulvaney, E. Nolan, M. Parker, I. Natoni, A. Lynch, K. Ryan, A.E. Szegezdi, E. Krawczyk, J. Murphy, P. O'Dwyer, M.